AC
COGT icon

Athanor Capital’s Cogent Biosciences COGT Stock Holding History

Athanor Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,575
Closed -$248K – 45
2018
Q1 		$248K Buy
+5,575
New +$248K 0.11% 63

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Athanor Capital's COGT Position: Q2 2018 in Review

Athanor Capital sold out of Cogent Biosciences (COGT) in Q2 2018, closing a stake of 5,575 shares — an estimated $248K sold.

Athanor Capital first reported a position in COGT in Q1 2018 and held it in 1 quarter. The position peaked at $248K in Q1 2018. 44 funds tracked by Wall St. Rank hold COGT as of Q2 2018.

  • Athanor Capital reported no remaining Cogent Biosciences position as of Q2 2018 after selling out during the quarter.
  • Athanor Capital sold 5,575 Cogent Biosciences shares in Q2 2018, an estimated $248K.
  • Athanor Capital first reported a position in Cogent Biosciences in Q1 2018 and held it in 1 quarter.
  • Athanor Capital's Cogent Biosciences position peaked at $248K in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2018.

Based on Athanor Capital's 13F filing for Q2 2018, filed 13 Aug 2018.